Tag Archive for PRO/EDR> Meningococcal disease, eculizumab: complement deficiency, increased risk
PRO/EDR> Meningococcal disease, eculizumab: complement deficiency, increased risk
Meningitis - Neisseria -- Worldwide/UnknownMcNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR"Use of eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a 1000-fold to 2000-fold increased incidence of meningococcal disease (1). Administration of meningococcal vaccines is recommended for patients receiving eculizumab before beginning treatment (2,3). Sixteen cases of meningococcal disease were identified in eculizumab recipients in the United States Read more [...]
